Nasal Glucagon Kit: Technical Pros and Cons for Emergency Use
Abstract: Nasal glucagon kits offer a needle-free emergency treatment for severe hypoglycemia, leveraging a synthetic peptide analog (e.g., dasiglucagon) for rapid systemic absorption. Compared to injectable glucagon, nasal delivery eliminates reconstitution errors and needle phobia, improving caregiver usability. However, limitations include higher cost ( $280–$350/dose vs. $150 for injectable), lower bioavailability ( 30–40% vs. 100%), and potential nasal congestion interference. Leading brands (Baqsimi vs. Gvoke) show comparable efficacy ( 99% rescue success within 30 min) but differ in device design and storage stability (Baqsimi: room temp, 24-month shelf life). The global glucagon market is projected to grow at 8.2% CAGR (2023–2030), driven by diabetes prevalence and non-injectable innovation. Regulatory approvals (FDA, EMA) and GMP-certified peptide manufacturing are critical for quality assurance.